文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Rigosertib逆转Noonan综合征中的肥厚型心肌病

Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome.
PubMed 文献 · Circulation · 2026-08-18

本研究通过果蝇RASopathy模型药物筛选发现rigosertib,并在Raf1L613V/+敲入小鼠中治疗6周,显著改善左室腔径、后壁厚度、心脏质量及心肌细胞大小,逆转肥厚型心肌病,并改善骨骼生长和颅面异常。

要点

  • Rigosertib在果蝇RASopathy模型中减轻心脏肥厚,效果优于trametinib。
  • 在Raf1L613V/+小鼠中治疗6周可逆转心脏肥厚并正常化胎儿基因表达。
  • Rigosertib还改善骨骼生长和颅面异常等Noonan综合征相关表型。

核心结论

  • Rigosertib可正常化并逆转RASopathy相关肥厚型心肌病及其他Noonan综合征特征,支持其作为RAF1相关HCM的潜在治疗药物。

研究设计与样本

  • 在表达RASopathy相关转基因的果蝇模型中进行临床相关化合物药物筛选,并评估rigosertib对心脏肥厚的作用。
  • 在Raf1L613V/+敲入小鼠中给予rigosertib治疗6周,通过超声心动图、组织学和分子分析评估心脏结构与功能。

主要发现

  • Rigosertib在一组转基因果蝇RASopathy模型中有效,提示对多种疾病变异有活性。
  • 在心脏靶向果蝇模型中,rigosertib减轻心脏肥厚且优于trametinib。
  • 在Raf1L613V/+小鼠中,治疗6周显著改善左室腔径、后壁厚度、心脏质量和心肌细胞大小,逆转心脏肥厚。
  • Rigosertib正常化胎儿基因表达并抑制原代心肌细胞中ERK和AKT信号。
  • Rigosertib显著改善骨骼生长和颅面异常等其他Noonan综合征相关特征。

临床怎么用

  • Rigosertib可能成为RAF1相关肥厚型心肌病的候选治疗药物,但需进一步临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RASopathies constitute a group of rare genetic disorders caused by mutations in genes along the canonical RAS/mitogen-activated protein kinase (MAPK) signaling pathway, affecting cell growth and differentiation. These syndromes, which include Noonan syndrome (NS), are characterized by developmental delays, distinctive facial dysmorphia, and cardiac defects, notably hypertrophic cardiomyopathy (HCM). Despite their prevalence and impact, therapeutic options for RASopathies remain limited. Rigosertib, a novel dual RAS/MAPK and phosphatidylinositol 3-kinase (PI3K)/AKT pathway inhibitor, is currently in clinical trials for treatment of melanoma and recessive dystrophic epidermolysis bullosa. Here, we identify rigosertib as a candidate therapy for RAF1-associated HCM. METHODS: We performed a drug screen of clinically relevant compounds in transgenic Drosophila models of RASopathies to identify candidate therapeutics. Cardiac-targeted Drosophila models expressing RASopathy-associated transgenes were used to evaluate the effects of rigosertib on cardiac hypertrophy and compare its efficacy with the mitogen-activated protein kinase kinase (MEK) inhibitor trametinib. Therapeutic efficacy was further assessed in a mammalian model using Raf1L613V/+ knock-in mice treated with rigosertib for 6 weeks. Cardiac structure and function were evaluated by echocardiography, histology, and molecular analyses, including assessment of cardiomyocyte size, fetal gene expression, and extracellular signal-regulated kinase/AKT signaling. Additional NS-associated phenotypes, including skeletal growth and craniofacial abnormalities, were also evaluated. RESULTS: Rigosertib was effective across a panel of transgenic Drosophila RASopathy models, suggesting activity against multiple disease variants. In cardiac-targeted fly models, rigosertib reduced cardiac hypertrophy and outperformed trametinib. In Raf1L613V/+ mice, 6 weeks of treatment significantly improved left ventricular chamber dimension, posterior wall thickness, heart mass, and cardiomyocyte size, resulting in reversal of cardiac hypertrophy. Rigosertib also normalized fetal gene expression and inhibited extracellular signal-regulated kinase and AKT signaling in primary cardiomyocytes. In addition to reversing cardiac pathology, rigosertib significantly improved other NS-associated features, including increased bone growth and correction of craniofacial abnormalities. CONCLUSIONS: Together, our findings suggest that rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features, supporting its development as a promising treatment for RAF1-associated HCM and, potentially, other RASopathy-dependent pathologies. This study not only highlights the therapeutic potential of rigosertib but also demonstrates the utility of an integrated approach using Drosophila and mammalian models to elucidate drug effects across complex biological systems.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Legler L, Marchetti K, Xu B, et al. Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome. Circulation. 2026. PMID: 42610277. doi:10.1161/CIRCULATIONAHA.126.080188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。